| Catalog No. | Size | Price (USD) |
| 40069-MM12-20 | 20 µL | $118.49 |
| 40069-MM12-100 | 100 µL | $340.51 |
General Information
| Product name | MERS-CoV Spike S2 Antibody, Mouse MAb |
| Validated applications | WB (FAQ Protocol), ELISA (FAQ Protocol) |
| Application notes | IHC, FCM, IF, IP et al. applications haven't been validated. (Antibody's applications haven't been validated with corresponding virus positive samples. Optimal concentrations/dilutions should be determined by the end user.) |
| Specificity | The antibody reacts with MERS-CoV (NCoV / Novel coronavirus) full-length Spike protein (S protein). Has cross-reactivity in ELISA and WB with MERS-CoV Spike Protein (Cat # 40069-V08B) MERS-CoV Spike/S2 Protein (Cat # 40070-V08B) No cross-reactivity in ELISA and WB with MERS-CoV Spike/S1 Protein (Cat# HPLC-40069-V08H) MERS-CoV Spike/RBD Protein fragment (Cat# 40071-V08B1) |
| Immunogen | Recombinant MERS-CoV (NCoV / Novel coronavirus) Spike Protein (ECD, aa 1-1297) (Catalog#40069-V08B) |
| Preparation | This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant MERS-CoV (NCoV / Novel coronavirus) Spike Protein (Catalog#40069-V08B; AFS88936.1; Met1-Trp1297). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography. |
| Source | Monoclonal Mouse IgG1 Clone #12 |
| Purification | Protein A |
| Formulation | 0.2 μm filtered solution in PBS |
| Conjugate | Unconjugated |
| Form | Liquid |
| Shipping | This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Storage | This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles. |
Image / Experimental Information
| Image 1 Description | Anti-MERS-CoV Spike/S2 mouse monoclonal antibody at 1:5000 dilution. Lane A: MERS-CoV Spike Protein (S1+S2 ECD, aa 1-1297) (Cat#40069-V08B) 40ng Lane B: MERS-CoV Spike/S1 Protein (S1 Subunit, aa 1-725) (Cat#HPLC-40069-V08H) 40ng Lane C: MERS-CoV Spike/S2 Protein (S2 Subunit, aa 726-1296) (Cat#40070-V08B) 40ng Lane D: MERS-CoV Spike/RBD Protein fragment (RBD, aa 367-606) (Cat#40071-V08B1) 40ng Secondary Goat Anti-Mouse IgG (H+L)/HRP at 1/10000 dilution Developed using the ECL technique. Performed under reducing conditions. |
| Image 1 Alt Text | MERS-CoV Coronavirus spike Western blot (WB) 38822 |
| Image 1 URL | Source image |
Background Information
| Description | The spike (S) glycoprotein of coronaviruses contains protrusions that will only bind to certain receptors on the host cell. Known receptors bind S1 are ACE2 (angiotensin-converting enzyme 2), DPP4 (dipeptidyl peptidase-4), APN (aminopeptidase N), CEACAM (carcinoembryonic antigen-related cell adhesion molecule), Sia (sialic acid), O-ac Sia (O-acetylated sialic acid). The spike is essential for both host specificity and viral infectivity. The term 'peplomer' is typically used to refer to a grouping of heterologous proteins on the virus surface that function together. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. It's been reported that SARS-CoV-2 (COVID-19 coronavirus, 2019-nCoV) can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. The main functions for the Spike protein are summarized as: Mediate receptor binding and membrane fusion; Defines the range of the hosts and specificity of the virus; Main component to bind with the neutralizing antibody; Key target for vaccine design; Can be transmitted between different hosts through gene recombination or mutation of the receptor binding domain (RBD), leading to a higher mortality rate. |
| References |
|
title: Functionality and translation fidelity characterization of mRNA vaccines using platform based mass spectrometry detection.
authors: Alyssa Q Stiving; Benjamin W Roose; ...; Xuanwen Li
journal: NPJ vaccines
date: 2025-02-23
pmid: 39988579
cited_by_count: 4
techniques: Blocking Assay; Simple Western; Software; Western Blot
bioz_score: 93
title: Enabling functionality and translation fidelity characterization of mRNA-based vaccines with a platform-based, antibody-free mass spectrometry detection approach
authors: Stiving Alyssa Q.; Roose Benjamin W.; ...; Li Xuanwen
journal: bioRxiv
date: 2024-05-14
doi: 10.1101/2024.05.14.594137
cited_by_count: 0
techniques: Blocking Assay; Simple Western; Software; Western Blot
bioz_score: 93
title: Pseudotyping Improves the Yield of Functional SARS-CoV-2 Virus-like Particles (VLPs) as Tools for Vaccine and Therapeutic Development
authors: Andrew J. Zak; Trang Hoang; ...; József Tőzsér
journal: International Journal of Molecular Sciences
date: 2023-09-27
pmid: 37834067
pmcid: 10572262
cited_by_count: 3
techniques: Binding Assay; Enzyme-linked Immunosorbent Assay; Incubation; Labeling; Neutralization; Recombinant; Variant Assay
bioz_score: 91
